|
Company Shares of Fresenius Medical Care Corporation Drops by -5.5% - News Watch International |
 |
|
Fresenius Medical Care Corporation (NYSE:FMS) has lost 5.5% during the past week and dropped 1.11% in the last 4 weeks. The shares are however, negative as compared to the S&P 500 for the past week with a loss of 6.59%. Fresenius Medical Care Corporation (NYSE:FMS) has underperformed the index by 2.38% in the last 4 weeks. Investors should watch out for further signals and trade with caution. Fresenius Medical Care AG & Co. KGAA has dropped 1.79% during the last 3-month period . Year-to-Date the stock performance stands at 11.25%.
The company shares have rallied 20.93% in the past 52 Weeks. On June 4, 2015 The shares registered one year high of $44.34 and one year low was seen on October 16, 2014 at $32.4. The 50-day moving average is $42.55 and the 200 day moving average is recorded at $41.2. S&P 500 has rallied 8.5% during the last 52-weeks. The company has received recommendation from many analysts. 2 analysts have rated the company as a strong buy. The shares have been rated as hold from 4 Wall Street Analysts. 1 analysts have suggested buy for the company. Shares of Fresenius Medical Care Corporation (NYSE:FMS) ended Friday session in red amid volatile trading. The shares closed down 0.14 points or 0.34% at $40.9 with 97,639 shares getting traded. Post opening the session at $41.22, the shares hit an intraday low of $40.84 and an intraday high of $41.31 and the price vacillated in this range throughout the day. The company has a market cap of $25,534 million and the number of outstanding shares have been calculated to be 624,304,000 shares. The 52-week high of Fresenius Medical Care Corporation (NYSE:FMS) is $44.34 and the 52-week low is $32.4.
Institutional Investors own 2% of Company shares. During last 3 month period, 1.28% of total institutional ownership has changed in the company shares. Fresenius Medical Care AG & Co KGaA is a Germany-based kidney dialysis company that operates in the fields of dialysis care and dialysis products for the treatment of end-stage renal disease (ESRD). Its dialysis business is vertically integrated and offers products and services for the entire dialysis value chain, providing dialysis treatment at dialysis clinics it owns or operates and supplying these clinics with a range of products. The Company offers two types of dialysis treatment: Hemodialysis (HD), where the machine controls the blood from the patient through a special filter, the dialyzer, and Peritoneal Dialysis (PD), where the patients peritoneum is used as a dialyzing membrane. Its dialysis product portfolio includes chronic hemodialysis, home dialysis, renal pharmaceuticals, acute therapy, liver support, therapeutic apheresis, therapy support and water technology, among others. In addition, the Company sells dialysis products to other dialysis service providers.
NO COMMENTS
LEAVE A REPLY
|